High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center-Reference-Cited by-同舟云学术

High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center

Published:2023-01-27 Issue:2 Volume:31 Page:787-797
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacol

Author:

Bektaş Murat^ORCID,Yüce Servet,Ay Mustafa,Uyar Muhammed Hamdi,Önder Mustafa Erkut^ORCID,Kılıç Muhammed İkbal

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Immunology

Link

https://link.springer.com/content/pdf/10.1007/s10787-023-01138-8.pdf

Reference38 articles.

1. Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M et al (2021) Cancer and COVID-19: analysis of patient outcomes. Future Oncol 17(26):3499–3510. https://doi.org/10.2217/fon-2021-0121

2. Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K et al (2021) Clinical characteristics and predictors of 28-day mortality in 352 critically Ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health 11(1):98–104. https://doi.org/10.2991/jegh.k.200928.001

3. Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D et al (2021) Sex-based differences in severity and mortality in COVID-19. Rev Med Virol 31(6):e2223. https://doi.org/10.1002/rmv.2223

4. Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H et al (2021) Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol 39(5):30–36. https://doi.org/10.55563/clinexprheumatol/815tdt

5. Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H et al (2021) Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis 103:288–296. https://doi.org/10.1016/j.ijid.2020.11.149

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study;Scientific Reports;2024-05-29

2. Intravenous High-dose Anakinra Drops Venous Thrombosis and Myocardial Infarction in Severe and Critical COVID-19 Patients: A Propensity Score Matched Study;2024-03-11

3. Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study;Infectious Diseases and Clinical Microbiology;2024-03-08

4. Second‐line immunotherapy in new onset refractory status epilepticus;Epilepsia;2024-03-02

5. Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study;International Immunopharmacology;2024-03